An assessment of dexmedetomidine as an opioid-sparing agent after neonatal open thoracic and abdominal operations

J Perinatol. 2022 Mar;42(3):307-312. doi: 10.1038/s41372-021-01175-7. Epub 2021 Jul 26.

Abstract

Objective: To evaluate the efficacy of dexmedetomidine as an opioid-sparing agent in infants following open thoracic or abdominal operations.

Methods: Retrospective review of postoperative neonates who received IV acetaminophen with or without dexmedetomidine. The primary outcome was opioid dosage within the first ten postoperative days. Secondary outcomes included times to extubation, full feedings and discharge.

Results: 112 infants met inclusion criteria. Those managed with dexmedetomidine received 1.8-4.3 times more opioid on postoperative days 1-3, had longer times to extubation and trended towards longer lengths of hospital stay than infants who were not. Opioid was dosed >0.2 ME/kg on only 23% of days when the acetaminophen dose was >40 mg/kg/day and 10% of days when the acetaminophen dose was >45 mg/kg.

Conclusion: Dexmedetomidine may not be opioid sparing after major operations in neonates and its use delays recovery. IV acetaminophen dosed at 40 mg/kg/day or greater may yield the most substantial opioid-sparing effect.

MeSH terms

  • Acetaminophen / therapeutic use
  • Analgesics, Non-Narcotic* / therapeutic use
  • Analgesics, Opioid / therapeutic use
  • Dexmedetomidine* / therapeutic use
  • Humans
  • Infant
  • Infant, Newborn
  • Length of Stay

Substances

  • Analgesics, Non-Narcotic
  • Analgesics, Opioid
  • Acetaminophen
  • Dexmedetomidine